Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$6.54 USD
+0.31 (4.98%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.01 (0.15%) 6:40 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Zevra Therapeutics, Inc. [ZVRA]
Reports for Purchase
Showing records 21 - 30 ( 30 total )
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
To Acquire ACER By YE23, Making Good on Orphan Drug Company Promise; $25 PT
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
2Q23: IH Data Arimoclomol NDA in 2H23, Ample Funds Provide Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
1Q23: IH Data Arimoclomol NDA in 2023, Ample Funds Provide Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Will Run Several Small Phase 1s Before Furthering KP1077 In Narcolepsy
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
New SDX Patent Issued, Helps Found Sleep Data Initiative Data Platform
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
Company: Zevra Therapeutics, Inc.
Industry: Medical - Drugs
4Q22: Data Coming in 2023, Funding Into 2026 Provides Ample Flexibility
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J